草酸铂联合异长春花碱治疗晚期NSCLC

Oxaliplatin Plus Vinorelbine in the Treatment of Advanced Non-small Cell Lung Cancer

摘要: 目的研究草酸铂(Oxaliplatin,LOHP)联合异长春花碱(Vinorelbine,NVB)组成的NO方案治疗晚期非小细胞肺癌(nonsmallcelllungcancer,NSCLC)的近期、远期疗效和毒副反应。方法77例均为晚期NSCLC患者。化疗方案:LOHP130mg/m2,静滴,第1天;NVB25～30mg/m2,静注,第1、8天,3～4周为1周期。结果有效率为33.78%,临床受益反应率77.03%;初治与复治有效率分别为39.29%和16.67%,差异有显著性意义(P<0.05),初治与复治的临床受益反应率差异有非常显著性意义(P<0.01);治疗后中位缓解期为22周;中位生存期为40周;一年生存率为39.19%。主要毒副反应是:Ⅰ～Ⅱ度周围神经炎发生率为44.59%,静脉炎发生率为78.38%,Ⅲ～Ⅳ度恶心/呕吐发生率仅4.05%。结论NO方案治疗晚期NSCLC有较好的近期疗效和远期疗效,组临床受益反应率较高,恶心/呕吐和骨髓抑制轻,可作为晚期NSCLC的一线化疗方案。

Abstract: Objective The objective of this article is to evaluate the response,toxicity and survival time of NO regimen\Oxaliplation (LOHP) plus vinorelbine(NVB)\ in the treatment of advanced NSCLC. Methods A total of 77 cases with advanced NSCLC were included in study.All patients were received NVB \25mg/m 2 d_ 1 and d_ 8\ and LOHP \ every 3~4 weeks.The whole course of treatment consisted at least 2 cycles. Results The response and the clinical benefit response rates(CBRs) were 33.78% and 77.03% respectively.The re...